Compare Lufax Holding Ltd (LU) vs Novavax Inc (NVAX) Price & Performance

LU trades at $0.95, down 3.54% on the day, with a bearish technical signal from moving averages but a bullish oscillator reading. The company reported a net loss of $2.10 billion in 2025 on revenue of $23.11 billion, with negative net income margins and ROE. A 10:1 reverse stock split occurred on October 23, 2026, and recent news highlights regulatory challenges and balance sheet strength.

The outlook remains challenged by persistent losses and revenue declines, though deep value is suggested by a P/B of 0.07 and strong parent backing. Risks include regulatory tightening in China and elevated credit costs, but analyst consensus is 69% buy with potential catalysts from capital return events.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.